Results 181 to 190 of about 88,563 (282)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 618-628, March 2026.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker   +20 more
wiley   +1 more source

Potential neuroprotective and therapeutic agents and their mechanisms for irradiation‐induced brain injury

open access: yesIbrain, Volume 12, Issue 1, Page 96-122, Spring 2026.
In this review, agents such baicalein, troxerutin, epigallocatechin gallate, quercetin, melatonin, valproic acid, lithium, neurosteroid progesterone, as well as minocycline have been implicated as neuroprotective agents for irradiation‐induced neurological deficits. Also, agents such as glucocorticoids, methylphenidate, vitamin E, bisdemethoxycurcumin,
Seidu A. Richard   +2 more
wiley   +1 more source

Microbiome‐urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation

open access: yesiMetaOmics, Volume 3, Issue 1, March 2026.
This review elucidates the critical crosstalk between the urobiome and bladder cancer (BCa), mapping the landscape from ecological dysbiosis to clinical translation. We synthesize emerging evidence on microbial signatures that distinguish BCa patients, exploring key carcinogenic mechanisms including chronic inflammation, genotoxicity, and the gut ...
Haoxiang Xu   +14 more
wiley   +1 more source

Low-flow vascular malformations without arteriovenous shunting of the central nervous system: a pictorial review. [PDF]

open access: yesInsights Imaging
Nicolosi L   +13 more
europepmc   +1 more source

RNA‐Based Therapies for Inherited Metabolic Disorders

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Inherited metabolic disorders (IMDs) are a diverse and complex group of genetic conditions resulting from deficiencies in enzymes, transporters, or cofactors. These deficiencies lead to metabolic dysfunction and severe clinical consequences. Despite significant progress in understanding their molecular basis, treatment options remain limited ...
Reddy Sreekanth Vootukuri   +5 more
wiley   +1 more source

Pharmacodynamics, Efficacy, and Safety of Intraputaminal Eladocagene Exuparvovec Administered to Pediatric Patients With Aromatic L‐Amino Acid Decarboxylase Deficiency Using an MR‐Compatible Cannula: 48 Weeks of Follow‐Up

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Aromatic ʟ‐amino acid decarboxylase (AADC) deficiency is a rare pediatric neurotransmitter disorder that typically necessitates lifelong care, and that carries a risk of childhood mortality. Eladocagene exuparvovec gene therapy is designed to restore AADC production.
Daniel J. Curry   +22 more
wiley   +1 more source

Long‐Term Follow‐Up of Patients With Transaldolase Deficiency

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Transaldolase (TALDO) deficiency has a well‐characterized phenotype. However, there are few large cohort studies, and little is known about the long term, including the need for organ transplantation. Our aim was to share a long multicenter experience in managing these patients.
M. Scaglione   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy